From PCOS to PMOS

When a condition affects more than 170 million women and 70% of them go undiagnosed, the problem isn’t just medical — it’s also in the name. For nearly 90 years, one of the most common hormonal disorders in women has been defined by something it doesn’t actually cause. In May 2026, that finally changed.

What is PCOS?

PCOS stands for Polycystic Ovary Syndrome — for decades the standard name for a hormonal and metabolic disorder affecting 1 in 8 women of reproductive age worldwide. Common features include:

Irregular or absent periods
Difficulty ovulating and infertility
Elevated levels of male hormones (androgens)
Excess facial or body hair
Acne
Weight gain or difficulty losing weight
Insulin resistance
Increased risk of type 2 diabetes and cardiovascular disease
Mental health challenges including depression and anxiety

The WHO estimates the condition affects 6–13% of women of reproductive age worldwide. The name came from early observations that affected ovaries appeared to have clusters of cysts — but as science advanced, that turned out to be a misleading description. Despite the name, many people with PCOS do not have ovarian cysts at all. The structures seen on ultrasound are actually immature follicles, not true cysts.

What is PMOS?

PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. It is the new official global name for the exact same condition. The condition itself hasn’t changed — but the name has been rewritten to reflect what is actually happening in the body.

Polyendocrine: recognizes that multiple hormone systems are imbalanced, not just the reproductive ones
Metabolic: highlights the condition’s significant impact on metabolism — specifically insulin resistance, weight, and diabetes risk — which affects approximately 85% of people with the condition
Ovarian: acknowledges the role of ovarian function and ovulation without using misleading terminology
Syndrome: reflects that this is a cluster of related symptoms, not a single-cause disease

Who was behind the change?

The renaming was driven by the Global Name Change Consortium — a purpose-built coalition of experts, researchers, clinicians, and patient organizations assembled specifically for this effort. Key leaders include Professor Helena Teede, Director of Monash University’s Monash Centre for Health Research & Implementation, who led the process after spending decades researching the condition and witnessing its patient impact firsthand. She worked alongside Professor Terhi Piltonen (AE-PCOS Society President, Finland), Anuja Dokras (AE-PCOS Society, US), and Rachel Morman (Chair of Verity PCOS UK), with 56 patient and international medical organizations including the Endocrine Society.

When Was the Change First Brought Up?

Calls to rename the condition are not new. Researchers and clinicians had been questioning the term PCOS for many years on the grounds that it was scientifically misleading. The US National Institutes of Health (NIH) recommended exploring a new name as early as 2012. In 2015, experts and patient advocates met in Sicily and agreed the name was inaccurate — but could not yet settle on a replacement. Surveys followed in 2017 and 2023, and a final global survey in 2025 reached nearly 15,000 stakeholders.

In total, the formal international process involved more than 22,000 people across six continents — clinicians, researchers, patients, and advocates — over roughly a decade of consultation, debate, and consensus building. The final official name PMOS was published in The Lancet on May 12, 2026, and presented at the European Congress of Endocrinology in Prague.

Why Did It Take So Long?

Several factors combined to make this one of the most complex disease-renaming processes in medical history.

1. The condition itself is complex: Researchers needed a name that accurately represented the hormonal, metabolic, and reproductive aspects of the condition without creating new confusion. That required years of research to establish that PCOS was not primarily a cystic ovarian disorder, but a polyendocrine metabolic disease — a conclusion only recently confirmed by large-scale genomic studies.

2. Global consensus was required: The 2015 Sicily meeting broke down precisely because experts couldn’t agree. The condition presents differently across patients — it has multiple phenotypes and no single unifying mechanism — which made naming it accurately genuinely difficult. Ultimately, agreement was needed across endocrinologists, gynecologists, fertility specialists, researchers, patient advocates, international medical societies, and cultural boundaries spanning 195 countries.

3. Medical terminology changes slowly by design: Updating clinical guidelines, diagnostic criteria, research literature, disease classification systems, insurance codes, and health records worldwide requires coordination with the WHO and other global health bodies. The stakes were high: a poorly managed transition risked disrupting healthcare codes, insurance coverage, and ongoing clinical trials across the globe.

4. The science kept evolving: New genomic research published in Nature Genetics in 2025 identified additional genetic pathways linked to the disorder — including mechanisms related to insulin signaling, ovarian function, and inflammatory pathways — further confirming that the old name no longer reflected current scientific understanding.

5. Patient input was treated as non-negotiable: More than 22,000 patients and health professionals were surveyed across multiple rounds to ensure the new name reflected lived experience, reduced stigma, avoided new misconceptions, and could be communicated clearly across cultures. That kind of inclusive, iterative process takes time.

6. There were legitimate dissenting concerns: The only two formal dissenters — Angela Grassi, CEO of the PCOS Nutrition Center, and Sasha Ottey, Executive Director of PCOS Challenge — raised two substantive objections. First, retaining “ovarian” in the new name excludes the possibility of a male expression of the condition, which early research is beginning to explore. Second, changing the acronym from PCOS to PMOS risks dismantling decades of patient community infrastructure — awareness campaigns, support networks, and clinical resources — that millions of people rely on to find help. Both concerns were outvoted, with the majority arguing that waiting on either issue would have further delayed care for women who had already waited long enough.

What Are the Effects and Benefits of the Name Change?

More accurate diagnosis: The WHO estimates that 70% of women with this condition currently go undiagnosed worldwide. The old name misled clinicians to focus on ovarian cysts as the defining feature. PMOS redirects attention to hormonal and metabolic dysfunction across the whole body, improving the likelihood of earlier and more accurate detection — including in patients who show no cysts on ultrasound.

Better and more comprehensive treatment: Because “metabolic” is now explicitly in the name, healthcare providers are far more likely to screen for and treat insulin resistance, cardiovascular risk, type 2 diabetes, and mental health conditions early — rather than focusing narrowly on fertility or menstrual regularity. PMOS also signals that care should involve endocrinologists, cardiometabolic specialists, mental health professionals, and dermatologists, encouraging multidisciplinary management rather than purely gynecological oversight.

Reduced stigma and confusion: The word “polycystic” led patients — and some clinicians — to believe the condition was defined by dangerous ovarian cysts that might rupture or require surgery. In reality, the structures seen on ultrasound are small, harmless immature follicles, and you don’t even need them to have the condition. Removing “cystic” from the name clears up a long-standing misnomer, reduces the dismissal of patients who don’t present with cysts, and better reflects the seriousness of what those living with the condition actually experience.

Improved research and funding: A scientifically accurate name gives researchers a clearer framework to study the condition’s subtypes and develop more targeted treatments. Crucially, it broadens the funding landscape — attracting investment from endocrinology, cardiology, and metabolic research, not just reproductive medicine. It also helps shape public health policy and standardize diagnostic criteria globally.

No disruption to existing patients: The diagnostic criteria for PMOS remain unchanged. If you have a PCOS diagnosis, it will now be referred to as PMOS. No new tests, no new appointments — just a more accurate label for what you already know.

How the Transition Will Work.

The name change doesn’t happen overnight. A structured 3-year rollout running to 2028 ensures the shift lands consistently across the global healthcare system. During this period, both PCOS and PMOS will appear side by side in medical records, lab reports, and patient materials. Multilingual educational resources are being developed to reach patients and clinicians across all world regions — not just English-speaking healthcare systems. Updates to electronic health records, insurance billing codes, and the WHO’s International Classification of Diseases (ICD) are being coordinated in parallel.

The rollout isn’t a benefit in itself — but without it, the real gains of the name change would be undermined by inconsistent adoption, billing failures, and patients falling through the cracks. It is the delivery vehicle that ensures better diagnosis, broader treatment, reduced stigma, and more accurate research funding actually reach the people who need them.

Bottom Line

PCOS has been officially renamed PMOS — Polyendocrine Metabolic Ovarian Syndrome — as of May 2026. The change is the result of a decade-long international effort involving thousands of experts, clinicians, and patients across six continents. The disease hasn’t changed. What has changed is that it finally has a name that tells the truth about what it is — a complex, whole-body hormonal and metabolic condition — and that distinction has real consequences for how it is diagnosed, treated, researched, and funded for the 170 million women living with it worldwide.

From PCOS to PMOS: The 90-Year Naming Mistake That Affected 170 Million Women — and Why It Finally Changed